eligibility_summary
Eligible studies included patients with HER2-positive breast cancer receiving neoadjuvant therapy, any cytotoxic chemotherapy regimen was allowed if drugs and doses were consistent across trials. Exclusions: metastatic disease, adjuvant therapy results, and duplicate reports—only the most recent/most informative publication per trial was retained.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial type: systematic review of neoadjuvant therapy in HER2+ breast cancer. Interventions: trastuzumab plus chemotherapy vs chemotherapy alone across included trials. Drug types/mechanisms: - Trastuzumab (IgG1 monoclonal antibody, anti-HER2/ERBB2): binds extracellular HER2, inhibits signaling/dimerization, promotes receptor downregulation, and triggers Fcγ-mediated ADCC. - Chemotherapy regimens included taxanes (paclitaxel, docetaxel, microtubule stabilizers), anthracyclines (epirubicin, topoisomerase II inhibitor/DNA intercalator), platinum (carboplatin, DNA cross-linker), alkylator (cyclophosphamide), antimetabolites (5‑fluorouracil, thymidylate synthase inhibitor, methotrexate, DHFR inhibitor). Targets/pathways: HER2-overexpressing tumor cells, HER2→PI3K/AKT and RAS/MAPK signaling, immune effector NK cells (ADCC), microtubules, DNA replication/repair and folate/thymidylate pathways. Reported overall pCR ≈42% with trastuzumab+chemo.